Takeda Pharmaceutical Company Limited logo

TAK

Takeda Pharmaceutical Company Limited

$13.44

Earnings Summary

Revenue
$1050869Mn
Net Profits
$-3018Mn
Net Profit Margins
-0.29%
PE Ratio
47.32

Highlights

Revenue:

Takeda Pharmaceutical Company Limited’s revenue jumped 9.91% since last year same period to $1050869Mn in the Q1 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -5.43% fall in its revenue since last 3-months.

Net Profits:

Takeda Pharmaceutical Company Limited’s net profit fell -109.69% since last year same period to $-3018Mn in the Q1 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -102.85% fall in its net profits since last 3-months.

Net Profit Margins:

Takeda Pharmaceutical Company Limited’s net profit margin fell -108.82% since last year same period to -0.29% in the Q1 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -103.02% fall in its net profit margins since last 3-months.

PE Ratio:

Takeda Pharmaceutical Company Limited’s price-to-earnings ratio after this Q1 2024 earnings stands at 47.32.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Takeda Pharmaceutical Company Limited post its latest quarter earnings

EPS Estimate Current Quarter
0.75
EPS Estimate Current Year
0.75

Highlights

EPS Estimate Current Quarter:

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current quarter stand at 0.75 - a 5381.69% jump from last quarter’s estimates.

EPS Estimate Current Year:

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current year stand at 0.75.

Key Ratios

Key ratios of the Takeda Pharmaceutical Company Limited post its Q1 2024 earnings

Earning Per Share (EPS)
-0.01
Return on Assets (ROA)
0.02
Return on Equity (ROE)
0.02

Highlights

Earning Per Share (EPS):

Takeda Pharmaceutical Company Limited’s earning per share (EPS) fell -108.78% since last year same period to -0.01 in the Q1 2024. This indicates that the Takeda Pharmaceutical Company Limited has generated -108.78% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Takeda Pharmaceutical Company Limited’s return on assets (ROA) stands at 0.02.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Takeda Pharmaceutical Company Limited’s return on equity (ROE) stands at 0.02.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-06-26
-0.01
-0.01
54.23%